-
ZGC Shuimu Medtech Raises RMB 100M in Series A+ Round Led by Yijing Capital
•
Beijing-based ZGC Shuimu Medical Technology Services Group, China’s first private third-party medical device testing institution, has reportedly raised RMB 100 million (USD 18.8 million) in a Series A+ financing round. The round was led by Yijing Capital and Green Pine Capital Partners. This follows the company’s Series A financing round…
-
Innovita Biological Technology’s IPO Raises USD 131.3M for POCT Expansion
•
Innovita Biological Technology Co., Ltd, a Beijing-based point-of-care testing (POCT) specialist, is set to make an initial public offering (IPO) of 34.02 million shares on Shanghai’s Sci-Tech Innovation Board (STAR). The shares are priced at RMB 26.06 (USD 3.86) each, with the listing expected to raise RMB 887 million (USD…
-
Fidia Farmaceutici’s Hyalubrix 60 Shows Promise in Treating Arthropathy at Hainan Hospital
•
Italy-based Fidia Farmaceutici S.p.A announced that its Hyalubrix 60, a prefilled syringe with sodium hyaluronate solution for intra-articular injection, has successfully completed treatment in four patients at Hainan General Hospital’s Lecheng branch. Product ProfileHyalubrix 60 is designed to restore the viscoelastic properties of knee and hip synovial fluid. It serves…
-
Gritgen Therapeutics Secures Hundreds of Millions in A-Round Financing for Gene Therapy Pipeline
•
Gritgen Therapeutics, a leading gene therapy drug developer based in Suzhou, has announced the successful completion of a A-round financing round worth several hundred million yuan. The financing was led by Sequoia China, with participation from Sunlight Insurance, Qingsong Capital, and Beijing Life Science Park Venture Fund. Existing shareholders including…
-
Shenzhen-Based Pregbio Raises Funds for Non-Invasive Prenatal Gene Detection
•
Pregbio, a Shenzhen-based non-invasive prenatal gene detection company, has reportedly raised an undisclosed amount of money in an angel financing round. The sole contributor to the round was ASB Ventures. The proceeds will be used to promote early screening and diagnosis of preterm labor and pre-eclampsia, non-invasive prenatal screening, and…
-
Novartis Cuts Back on US Development of BeiGene’s PD-1 Inhibitor Tislelizumab
•
Novartis AG (NYSE: NVS), BeiGene’s partner, revealed in its Q3 2022 earnings report that it is scaling back the US development of the programmed death-1 (PD-1) inhibitor tislelizumab. The firm no longer plans to file a New Drug Application (NDA) in the US for nasopharyngeal carcinoma (NPC) and has ended…
-
Bayer Initiates US Recall of TRK Inhibitor Vitrakvi Due to Mold Contamination
•
Germany-based Bayer (ETR: BAYN) has announced a voluntary recall of a specific lot of its tropomyosin receptor kinase (TRK) inhibitor Vitrakvi (larotrectinib) in the US market following the detection of contamination by the Penicillium brevicompactum mold in the oral solution. While no adverse events have been reported, Bayer has advised…
-
Latin America Accelerates COVID-19 Fight with Vaccine and Treatment Initiatives Across the Region
•
Latin America is ramping up its contributions to the worldwide race for COVID-19 vaccines and treatments. Cuba’s state-owned BioCubaFarma, through its Center for Genetic Engineering and Biotechnology (CIGB), has designed a vaccine candidate and is advancing its development in collaboration with China’s Research and Development Center in Yongzhou, Hunan’s Industrial…
